INTRODUCTION
The growth of cancerous prostate cells requires stimulation of the androgen receptor (AR) by androgens, the most potent of which is dihydrotestosterone (DHT). Advanced prostate cancer usually initially regresses with gonadal testosterone (T) deprivation therapy (i.e., medical or surgical castration), but it almost always eventually progresses as castration-resistant prostate cancer (CRPC) (Attard et al., 2009; Penning, 2010; Scher and Sawyers, 2005; Sharifi et al., 2005; Yuan and Balk, 2009) . The CRPC phenotype is driven by a gain of function in the androgen receptor (AR) that is usually accompanied by intratumoral DHT concentrations of about 1 nM, an amount sufficient to drive expression of AR-induced genes, including the TMPRSS2-ETS fusion oncogene (Geller et al., 1978; Luu-The et al., 2008; Montgomery et al., 2008; Sharifi, 2013; Titus et al., 2005; Tomlins et al., 2005) . The requirement for intratumoral androgen synthesis in driving CRPC progression is most clearly demonstrated by the survival benefit conferred by abiraterone acetate, a drug that blocks androgen synthesis by inhibiting 17a-hydroxylase/ 17,20-lyase (CYP17A1), and enzalutamide, a potent AR antagonist that blocks DHT access to the AR ligand-binding domain (Barrie et al., 1994; de Bono et al., 2011; Scher et al., 2012; Tran et al., 2009) . Intratumoral synthesis of DHT from precursors that are secreted from the adrenal gland occurs through a pathway that circumvents T (Chang et al., 2011) . This synthesis requires three enzymes: 3b-hydroxysteroid dehydrogenase (3bHSD; encoded by HSD3B), steroid-5a-reductase (SRD5A), and 17b-hydroxysteroid dehydrogenase (17bHSD) isoenzymes (see Figure 1A ) (Chang et al., 2011; Knudsen and Penning, 2010) . Nonetheless, increased DHT synthesis in CRPC has not yet been ascribed to any mutations in genes encoding components of the steroidogenic machinery. 3bHSD oxidizes 3b-hydroxyl to 3-keto and isomerizes D 5 to D 4 (see Figure 1A ), reactions that together make this step practically irreversible by an enzyme that is required for all possible pathways that lead to the synthesis of DHT (Evaul et al., 2010) . HSD3B1 encodes for the peripherally expressed isoenzyme (3bHSD1) and has a germline single-nucleotide polymorphism (SNP) at position 1245 of HSD3B1, converting A / C, which exchanges an asparagine (N) for a threonine (T) at 3bHSD1 amino acid position 367.
Here, we show that CRPC sometimes expresses the 367T form of 3bHSD1 (3bHSD1(367T)), which increases metabolic flux from dehydroepiandrosterone (DHEA) via the 5a-androstanedione (5a-dione) pathway to DHT by protein resistance to ubiquitination and degradation rather than increased catalytic activity. Selection for 3bHSD1(367T) is evident from somatic mutation in human CRPC tumors, by loss of heterozygosity (LOH) of the wild-type copy in patients with germline heterozygous inheritance, and from the generation and expression of the same somatic mutation occurring in a mouse xenograft model treated with abiraterone acetate.
RESULTS

Cells with 3bHSD1(367T) Have Increased Flux to DHT
Conversion of DHEA by 3bHSD1 to D 4 -androstenedione (AD) is a proximal step in peripheral tissues for metabolism from adrenal precursors to DHT (Lorence et al., 1990; Simard et al., 2005) . Two cell lines derived from patients with CRPC have widely disparate flux from DHEA to AD ( Figure 1A ), despite comparable expression of transcripts encoding both 3bHSD1 and 3bHSD2 ( Figure S1A (Chang et al., 2011) , is further evident by limited accumulation of downstream metabolites and absence of DHEA concentration-dependent increases in AR-regulated PSA and TMPRSS2 ( Figure 1B ). Sequencing the exons of both HSD3B isoenzymes reveals a single nonsynonymous substitution ( Figure 1C ) at position 1245 of HSD3B1, converting A / C, and exchanges an asparagine (N) for a threonine (T) at 3bHSD1 amino acid position 367 in LNCaP, but not in LAPC4. To further test the association between HSD3B1 sequence and steroid metabolism, other human prostate cell lines were investigated. The presence of wild-type (1245A) and variant (1245C) HSD3B1 sequences in other prostate cancer and immortalized prostate cell lines is also concordant with ''slow'' and ''fast'' flux from DHEA to AD, respectively ( Figure S1B ). The kinetic properties of recombinant 3bHSD1(367N) and 3bHSD1(367T) proteins, however, do not explain the differences in steroid metabolism between cells expressing each protein ( Figure 1D ). Western blot was performed to determine if the allele encoding 3bHSD1(367T) is associated with a greater amount of protein in these cells. Both models that encode for 3bHSD1(367T) have increased 3bHSD1 protein compared with the models that have wild-type sequence ( Figure 1E ).
Androgen Deprivation Selects for HSD3B1(1245C)
The HSD3B1(1245C); 3bHSD1(367T) allele occurs as a germline SNP variant (rs1047303; 22% allele frequency) (Shimodaira et al., 2010) but might also occur as a somatic mutation in prostate cancer. Although germline homozygous HSD3B1(1245C) inheritance cannot be ruled out, the most likely scenarios accounting for the sole presence of the HSD3B1(1245C) allele evident in both LNCaP and VCaP, given the low expected frequency of homozygous HSD3B1(1245C) inheritance, are either germline heterozygous inheritance followed by loss of heterozygosity (LOH) of the wild-type allele or germline homozygous wild-type inheritance followed by somatic mutation of 1245 A / C. To identify the existence of these possible mechanisms of HSD3B1(1245C) selection in human tumors, matching germline and tumor DNA were sequenced from men with CRPC. Genomic DNA was isolated from CRPC and normal tissue from patients treated at the University of Texas Southwestern Medical Center (UTSW) and from the University of Washington (UW) rapid autopsy program (Montgomery et al., 2008) . Patient and tumor characteristics are available in Table  S1 . Of 40 men with CRPC, the germline of 25, 11, and 4 individuals is homozygous wild-type HSD3B1(1245A), heterozygous and homozygous variant HSD3B1(1245C), respectively. Three of 25 (12%) CRPC tumors with homozygous HSD3B1(1245A) inheritance have acquired the HSD3B1(1245C) allele (Figure 2A ). Expression of HSD3B1(1245C) transcript was confirmed in the one available fresh-frozen tumor. It is highly likely that the observation of three identical de novo mutations occurring in 25 patients is due to selection rather than chance alone, with a high degree of statistical significance (p = 1.47 3 10 À13 ), using the binomial method and assuming a mutation rate of 4 per 1,000,000 base pairs (Greenman et al., 2007) . Of 11 CRPC tumors with heterozygous inheritance, three (27%) have LOH of the HSD3B1(1245A) allele, resulting in the HSD3B1(1245C) allele being predominantly detectable ( Figure 2B ). In these three tumors, LOH of adjacent heterozygous SNPs further confirms loss of this region of chromosome 1. In contrast, none of the 11 cases with heterozygous inheritance exhibited LOH of the HSD3B1(1245C) allele ( Figure S2A ). Two tumors (UW9 and UW25) with LOH of the HSD3B1(1245A) allele had tissue remaining for additional studies. Consistent with the findings in LNCaP and VCaP that only have the HSD3B1(1245C) allele, both of these tumors have abundant detectable 3bHSD1 protein ( Figure 2C ). In contrast, both tumors tested with heterozygous expression and homozygous HSD3B1(1245A) expression have little or no detectable 3bHSD1. Messenger RNA (mRNA) quantitation by qRT-PCR demonstrates that the increased 3bHSD1 protein abundance occurring specifically in the tumors with LOH is not attributable to transcript overexpression ( Figure S2B ). Both tumors with LOH robustly express AR and PSA, suggesting that flux to DHT sustained by 3bHSD1 protein functions to elicit AR signaling ( Figure 2C ).
Abiraterone inhibits CYP17A1 and weakly inhibits 3bHSD, further decreasing intratumoral androgen concentrations and extending survival in CRPC (de Bono et al., 2011; Li et al., 2012) ; therefore, conversion to the HSD3B1(1245C) allele encoding 3bHSD1(367T) might permit sustained androgen synthesis despite lower availability of precursors. To determine if abiraterone treatment selects for the HSD3B1(1245C) allele, genomic DNA from LAPC4 xenograft tumors grown in orchiectomized (legend continued on next page) mice treated with abiraterone or vehicle (n = 8 mice per treatment) was isolated and sequenced (Li et al., 2012) . The 1245C allele is detectable in 2 of 8 tumors (Abi #1 and Abi #2) in the abiraterone treatment group and no tumors in the vehicle group ( Figure 2D ). To confirm expression of the somatically acquired mutation in the abiraterone group, complementary DNA (cDNA) clones were generated and sequenced. The mutant HSD3B1(1245C) transcript encoding for 3bHSD1(367T) is confirmed in 12 of 21 (57%) cDNA clones sequenced from Abi #1 and 7 of 26 (27%) See also Figure S2 and Table S1 .
clones from Abi #2. In contrast, the mutant transcript is not present in any of the 37 cDNA clones obtained from two vehicletreated LAPC4 xenograft tumors.
Blocking 3bHSD1(367T) Inhibits DHT Synthesis, the AR Response, and CRPC To determine the role of 3bHSD1(367T) expression in regulating flux from DHEA to DHT and AR stimulation, endogenous expression was silenced in LNCaP using two independent lentiviral short hairpin RNAs (shRNAs) ( Figure 3A ). Blocking 3bHSD1 expression with both shRNAs inhibits flux from DHEA to AD, resulting in little or no detectable conversion to downstream 5a-dione and DHT ( Figure 3B ). Silencing expression of mutant 3bHSD1 and blocking flux to DHT impedes the expression of AR-regulated PSA and TMPRSS2 ( Figure 3C ), leading to inhibition of cell proliferation in vitro ( Figure 3D ). In vivo, depletion of endogenously expressed mutant 3bHSD1 significantly (legend continued on next page)
hinders CRPC growth in surgically orchiectomized mice (Figure 3E) . CRPC tumors that eventually develop from cell lines initially expressing lentiviral shRNA knockdown constructs regain 3bHSD1 protein, probably from selection for cells that have lost the shRNA construct ( Figure 3F ).
3bHSD1(367T) Is Resistant to Ubiquitination and Degradation
Endogenous expression of 3bHSD1(367T) appears to engender increased protein abundance compared to expression of 3bHSD1(367N) ( Figure 1E ). To determine if the underlying mechanism is due to an alteration in protein degradation, wild-type (HSD3B1(N)-HA) and (HSD3B1(T)-HA) constructs were generated and transiently expressed, and protein levels were compared following inhibition of translation with cycloheximide (CHX) treatment. The 367 N / T mutation substantially increases protein half-life from 2.1 to 27 hr ( Figure 4A ). Similar experiments with an alternative prostate cancer cell line (Figure S3A ) and with stable expression of lentiviral constructs confirm the longer half-life of 3bHSD1(367T) ( Figure S3B ). To determine whether increased degradation of wild-type protein is reversible with proteasome inhibition, cells were treated with MG132. Pharmacologic proteasome inhibition increases endogenous wild-type 3bHSD1(367N) in LAPC4 but does not increase 3bHSD1(367T) in LNCaP ( Figure 4B ), and polyubiquitinated endogenous 3bHSD1(367N) accumulates with MG132 treatment in LAPC4 ( Figure 4C ). In contrast, polyubiquitinated endogenous 3bHSD1(367T) is not increased in LNCaP with MG132 treatment ( Figure S3C) . A direct comparison of ubiquitination between HA-tagged wild-type and mutant protein by Ni-agarose pull-down demonstrates that 3bHSD1(367T) is resistant to polyubiquitination ( Figure 4D ), explaining decreased vulnerability to proteasome-mediated degradation and longer protein half-life.
AMFR Binds 3bHSD1(367N) and Is Required for Ubiquitination
We employed mass spectrometry to determine the lysine residue(s) ubiquitinated on 3bHSD1(367N). Ubiquitination is detectable on both K70 ( Figure 5A ) and K352 ( Figure 5B ) of 3bHSD1(367N). The effects of K352R and K70R single mutations and a double mutation on ubiquitination were assessed by Ni-agarose pull-down ( Figure 5C ). K352 appears to be a more critical site of ubiquitination than does K70, and mutation of both sites decreases ubiquitination greater than does either mutation alone. Autocrine mobility factor receptor (AMFR, also known as gp78) is a membrane-anchored ubiquitin ligase that functions through (E) 3bHSD1(367T) depletion blocks CRPC growth in LNCaP xenografts. Mice underwent surgical orchiectomy and DHEA pellet implantation concomitantly when xenograft tumors reached a threshold volume of 100 mm 3 . Fifteen mice were initiated in each cohort, 7, 8, and 10 mice in shCTRL, shHSD3B1 #1, and shHSD3B1 #2 groups, respectively, achieved a tumor volume of 100 mm 3 in eugonadal mice, underwent orchiectomy, and were included in the CRPC analysis.
The number of days from orchiectomy to tumor volume R600 mm 3 is shown. In the comparisons of shCTRL versus shHSD3B1 #1 and shHSD3B1 #2, p = 0.002 and 0.003, respectively, using a log rank test. the endoplasmic reticulum-associated protein degradation (ERAD) pathway (Song et al., 2005) . Eeyarestatin I (EerI) is a small molecule that inhibits protein degradation through the ERAD pathway (Wang et al., 2008 (Wang et al., , 2009 . Endogenous 3bHSD1(367N) protein increases in LAPC4 cells with EerI treatment, suggesting that the ERAD pathway is required for 3bHSD1(367N) degradation ( Figure 5D ). Stable isotope labeling by amino acids in cell culture (SILAC) coupled with high-resolution mass spectrometry was employed to identify candidate ubiquitin ligases in an unbiased manner that preferentially associate with 3bHSD1(367N) (Ong et al., 2002) . In this experiment, cells expressing 3bHSD1(367T)-HA and 3bHSD1(367N)-HA were grown in light and heavy media, respectively. AMFR was detected with a normalized protein ratio of 1.67 (derived from peptide ratios varying %17%) in a mixture of 3bHSD1 (367N) preferential physical association of AMFR with 3bHSD1(367N) protein (Figure 5E ). To assess the functional consequence of this interaction, AMFR was silenced using siRNA ( Figure 5F ). AMFR knockdown increases the abundance of 3bHSD1 protein, demonstrating the requirement of AMFR for 3bHSD1 degradation through the ERAD pathway. In contrast, silencing the alternative ubiquitin ligase SKP2 by siRNA had no detectable effect on 3bHSD1.
3bHSD1(367T) Increases DHT Synthesis
To determine if resistance to protein ubiquitination and degradation ascribed to 3bHSD1(367T) confers increased synthesis of DHT from precursor steroids, we expressed constructs that encode for 3bHSD1(367N), 3bHSD1(367T), or vector alone in LAPC4 cells and assessed metabolic flux from [ 3 H]-DHEA to downstream steroids. LAPC4 cells transiently transfected with the construct encoding for 3bHSD1(367T) exhibit increased flux from DHEA / AD / 5a-dione / DHT ( Figure 6A ). Equivalent expression of both transcripts was confirmed by qRT-PCR ( Figure 6B ). Stable lentiviral expression of 3bHSD1(367T) similarly confers increased flux from DHEA / AD / 5a-dione / DHT (Figure 6C) , with transcript expression comparable to wild-type transcript expression ( Figure 6D ). Finally, we determined that the 3bHSD1(367T) phenotype that accelerates flux from DHEA to DHT amplifies the response of androgen-regulated gene expression ( Figure 6E ) and hastens the time to the development of CRPC xenograft tumors ( Figure 6F ) in orchiectomized mice supplemented with DHEA to mimic human adrenal physiology. 3bHSD1(367T) tumors express higher levels of PSA transcript compared to 3bHSD1(367N) tumors, suggesting the presence of higher sustained DHT concentrations generated in 3bHSD1(367T) tumors ( Figure 6G ). Together, these findings support a mechanism that favors genetic selection for the allele encoding 3bHSD1(367T) in the setting of androgen depletion.
DISCUSSION
A major mechanism of resistance to frontline gonadal T depletion (or castration) therapy is an acquired metabolic capability, which allows CRPC tumors to sustain sufficient DHT concentrations for AR stimulation and tumor progression. This study identifies a gain-of-function mutation in the steroidogenic machinery that increases flux to DHT. Notably, whether CRPC utilizes the major adrenal pathway, or possibly de novo steroidogenesis from cholesterol, 3b-hydroxyl oxidation to 3-keto and D
5/4
isomerization occurring through 3bHSD enzymatic activity is required for all pathways culminating in T and/or DHT synthesis (Evaul et al., 2010) . Adrenal DHEA and DHEA-sulfate are typically present in abundant concentrations in human serum. In the context of intratumoral 3bHSD1(367N) expression, the clinical response to gonadal T depletion probably occurs in part due to the limited contribution of adrenal precursors to intratumoral DHT. Augmented 3bHSD activity occurring through increased protein abundance with 3bHSD1(367T) would therefore serve to open the floodgates on a proximal and otherwise rate-limiting step for the synthesis of DHT, resulting in the development of CRPC. Notably, in the setting of heterozygous inheritance, 3bHSD1 protein expression is markedly higher in tumors that have lost the wild-type HSD3B1(1245A) allele compared to tumors that retain the wildtype sequence ( Figure 2C ). This finding might occur because expression and colocalization of the wild-type 3bHSD1(367N) protein reinstates mutant 3bHSD1(367T) ubiquitination and subsequent degradation via dimerization or oligomerization. Nonetheless, engineered 3bHSD1(367T) expression engenders increased flux to DHT and development of CRPC despite endogenous 3bHSD1(367N) expression ( Figure 6 ). Therefore, the transition from sole 3bHSD1(367N) expression to mixed expression to dominant 3bHSD1(367T) expression probably represents a stepwise selection for an increased capacity for DHT synthesis. The population frequency of the HSD3B1(1245C) allele is approximately 22% but appears to vary widely by ethnicity (http://genome.ucsc.edu/). Other studies suggest that the HSD3B1(1245C) allele may raise aldosterone levels and increase the risk of essential hypertension (Shimodaira et al., 2010) . This is probably attributable to increased 3bHSD enzyme activity, which is required for aldosterone synthesis, although aldosterone is generally thought to require 3bHSD2. Interestingly, this phenotype appears to be more severe with homozygous HSD3B1(1245C). The observation of extremely high aldosterone with homozygous HSD3B1(1245C) is consistent with higher enzymatic activity and stepwise selection for sole 3bHSD1(367T) expression that occurs in CRPC. HSD3B1(1245C) has no consistent effect on risk of localized prostate cancer (Chang et al., 2002; Cunningham et al., 2007; Thomas et al., 2008) .
Although abiraterone potently inhibits androgen synthesis, clinical studies of urinary androgen metabolites in patients with CRPC treated with this drug have demonstrated that the block is incomplete and that the synthesis of residual androgen precursors persists (Attard et al., 2012) . This finding raises the possibility that tumor mechanisms that augment androgen synthesis from limited precursor steroids by increasing flux to DHT might contribute to abiraterone resistance . Our data demonstrating the selection and expression of 3bHSD1(367T) in a xenograft model of abiraterone resistance suggest a genetic mechanism for clinical resistance to abiraterone and that pharmacologic inhibition of 3bHSD1 might be a viable therapeutic strategy to overcome this resistance against tumors expressing the mutant enzyme. Despite the potent activity of the AR antagonist enzalutamide, its affinity for the ligand-binding domain of AR is lower than the affinity of DHT (Tran et al., 2009) . Increased metabolic flux from steroid precursors to DHT by 3bHSD1(367T) may therefore conceivably tip the scales in the favor of DHT and lead to enzalutamide resistance as well. The contribution of 3bHSD1(367T) in clinical resistance to abiraterone and enzalutamide, however, remain to be determined.
The past decade has brought to the fore the development of molecularly targeted therapies that are matched to specific disease-driving enzyme mutations present in a given patient.
These advances come mainly in the form of tyrosine kinase inhibitors that target gain-of-function mutations in these signaling enzymes. These include the examples of EGF receptor inhibitors matched with tumors harboring mutant EGF receptor in non-small-cell lung cancer and BRAF inhibitors for melanomas that are driven by BRAF mutations (Chapman et al., 2011; Kobayashi et al., 2005; Lynch et al., 2004) . In contrast, no examples of drug targeting based on enzyme mutations exist in the standard of care for metastatic CRPC. Although our demonstration is in a gain of function in a metabolic enzyme, rather than a signaling enzyme, we believe the underlying principle is the same, and our findings expose the opportunity for matching a mutant disease-driving enzyme biomarker with its cognate pharmacologic inhibitor.
EXPERIMENTAL PROCEDURES Steroid Metabolism Experiments
Steroid metabolism experiments were performed 12 hr after seeding cells by treatment with 1 ml serum-free medium containing [
3 H]-labeled DHEA (100 nM, 300,000-600,000 cpm; PerkinElmer). Aliquots of medium were collected for up to 48 hr and treated with b-glucuronidase (1,000 units; Sigma-Aldrich) at 65 C for 4 hr. Deconjugated steroids were extracted, evaporated under nitrogen stream, dissolved in 50% methanol, and injected on a Breeze 1525 system equipped with model 717 plus autoinjector (Waters), and steroid metabolites were separated on a Luna 150 3 3 mm, 3.0 mM C 18 reverse-phase column (Phenomenex). The column effluent was mixed with Liquiscint scintillation cocktail (National Diagnostics) and analyzed by a b-RAM model 3 in-line radioactivity detector (IN/US Systems). Steroid metabolism experiments with transient enzyme expression were performed with pCMV5-HSD3B1 (367N and 367T) constructs 24 hr after transfection and 12 hr after treatment with 25 mM cycloheximide (CHX). Steroid metabolism experiments with stable enzyme expression were performed after lentiviral infection with pLVX-Tight-Puro vector. Human tissues were obtained using Institutional Review Board-approved protocols at UT Southwestern and the University of Washington rapid autopsy program. Lentiviral constructs were made from miR30-styled shRNA sequences and cloned into the pGIPZ vector, and infected cells expressing the constructs were selected with 2 mg/ml puromycin. Gene expression was performed by qRT-PCR using the iTaq SYBR Green Supermix with the ROX kit (Bio-Rad) in an ABI-7500 Real-Time PCR machine (Applied Biosystems). Protein halflife was determined after transient transfection with pCMX-HSD3B1-HA (367N and 367T) plasmids, followed in 24 hr with 25 mM CHX in serumfree medium containing 100 nM DHEA. Cells stably expressing HA-tagged HSD3B1 (367N and 367T) in pLVX-Tight-Puro were used to determine protein half-life 24 hr after induction of protein expression with 2 ng/ml doxycycline and treatment with CHX. For details on all other experiments, including cell line and human tissue analyses, xenograft studies, gene expression studies, mass spectrometry, and other biochemical experiments, please refer to the Extended Experimental Procedures. 
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